Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    ibalizumab
Show Display Options
Rank Status Study
1 Recruiting Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1
Condition: HIV
Interventions: Drug: ibalizumab;   Drug: Optimized Background Regimen
2 Completed
Has Results
Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1
Condition: HIV
Intervention: Drug: Ibalizumab
3 Completed Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers
Condition: Prevention of Infection With HIV-1
Intervention: Biological: ibalizumab (biologic/MAb) for SC Injection or placebo
4 Recruiting Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
Condition: HIV
Interventions: Biological: ibalizumab;   Drug: Optimized Background Regimen (OBR)
5 Active, not recruiting Investigator-Sponsored Protocol - Continued Use of Ibalizumab
Condition: HIV Infections
Intervention: Drug: ibalizumab
6 Available Compassionate Use of Ibalizumab for the Treatment of HIV Infection
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: Dolutegravir;   Drug: Ibalizumab
7 Unknown  TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1
Condition: HIV Infections
Intervention: Drug: TNX-355

Indicates status has not been verified in more than two years